Forte Biosciences (FBRX) CFO receives 22,000 stock options grant

Rhea-AI Filing Summary

Forte Biosciences, Inc. reported that Chief Financial Officer Antony A. Riley received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $17.15 per share and expire on June 16, 2036.

According to the disclosure, all 22,000 option shares were held directly after the transaction, reflecting a compensation-related award rather than an open-market purchase. The footnotes state that, subject to continued service, one forty-eighth of the options will vest monthly starting on the Vesting Commencement Date of June 16, 2026, so the grant is scheduled to be fully vested four years after that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Riley Antony A

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 22,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 22,000 shares Exercise price: $17.15/share Expiration date: June 16, 2036 +3 more

6 metrics

Options granted 22,000 shares Stock Option (right to buy) grant to CFO

Exercise price $17.15/share Conversion or exercise price for granted options

Expiration date June 16, 2036 Option term end for 22,000-share grant

Vesting commencement June 16, 2026 Vesting Commencement Date under 2021 Equity Incentive Plan

Monthly vesting fraction 1/48 each month Equal monthly vesting over four years

Post-transaction derivative holdings 22,000 options Total stock options held directly after grant

Key Terms

Stock Option (right to buy), 2021 Equity Incentive Plan, Vesting Commencement Date, Grant, award, or other acquisition

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

2021 Equity Incentive Plan financial

"as defined in the 2021 Equity Incentive Plan"

Vesting Commencement Date financial

""Vesting Commencement Date" shall mean June 16, 2026."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/17/2026 - 04:56 PM Accepted by SEC EDGAR 06/17/2026 - 04:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riley Antony A

(Last) (First) (Middle)

C/O FORTE BIOSCIENCES, INC.

3060 PEGASUS PARK DR., BLDG 6

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Forte Biosciences, Inc. [ FBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$17.15	06/16/2026		A		22,000		(1)	06/16/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the total shares subject to the option shall vest every month following the Vesting Commencement Date such that all shares shall be fully vested on the four (4) year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 16, 2026.

	/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Forte Biosciences (FBRX) disclose in this Form 4 for its CFO?

Forte Biosciences disclosed that CFO Antony A. Riley received a grant of stock options for 22,000 shares. These options are compensation-related, have a $17.15 exercise price, and expire in June 2036, rather than representing an open-market share purchase or sale.

What are the key terms of Antony A. Riley’s Forte Biosciences stock option grant?

The grant covers 22,000 options on Forte Biosciences common stock at an exercise price of $17.15 per share. The options expire on June 16, 2036, and vest monthly over four years beginning June 16, 2026, contingent on Riley remaining a qualifying service provider.

How does the vesting schedule work for the Forte Biosciences CFO’s options?

The options vest in equal monthly installments, with one forty-eighth of the 22,000 shares vesting each month. Vesting begins on June 16, 2026, and continues for four years, provided Antony A. Riley continues as a service provider under the company’s 2021 Equity Incentive Plan.

Is the Forte Biosciences CFO’s Form 4 transaction a market buy or sell of FBRX shares?

No, the Form 4 reports a grant of stock options as compensation, not a market buy or sell. The transaction is coded as an acquisition (Code A) of derivative securities that can be exercised later at $17.15 per share, subject to the vesting schedule.

When do Antony A. Riley’s Forte Biosciences options expire and become fully vested?

The options expire on June 16, 2036, giving a long exercise window once vested. Vesting is scheduled monthly over four years starting June 16, 2026, so, assuming continued service, all 22,000 options are expected to be fully vested on the fourth anniversary of that date.